ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
MRI-guided Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 226624" data-attributes="member: 13851"><p>[MEDIA=youtube]F2IvVOWyVSE[/MEDIA]</p><p></p><p><em><strong>In this 19-minute presentation, Laurence Klotz, MD, Professor of Surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research, discusses the technology, procedure, outcomes, and regulatory environment surrounding MRI-guided transurethral ultrasound ablation (TULSA) treatment for patients with prostate cancer. He cites data from a clinical trial that demonstrates 96 percent of patients had a PSA reduction ≥75 percent at 12 months and at the 12-month MRI the median prostate volume had decreased from 41 to 4 cc (a decrease of 90 percent). Further, the treatment preserved continence and erectile function.</strong></em></p><p></p><p>[ATTACH=full]22967[/ATTACH]</p><p>[ATTACH=full]22968[/ATTACH]</p><p>[ATTACH=full]22969[/ATTACH][ATTACH=full]22970[/ATTACH]</p><p>[ATTACH=full]22971[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 226624, member: 13851"] [MEDIA=youtube]F2IvVOWyVSE[/MEDIA] [I][B]In this 19-minute presentation, Laurence Klotz, MD, Professor of Surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research, discusses the technology, procedure, outcomes, and regulatory environment surrounding MRI-guided transurethral ultrasound ablation (TULSA) treatment for patients with prostate cancer. He cites data from a clinical trial that demonstrates 96 percent of patients had a PSA reduction ≥75 percent at 12 months and at the 12-month MRI the median prostate volume had decreased from 41 to 4 cc (a decrease of 90 percent). Further, the treatment preserved continence and erectile function.[/B][/I] [ATTACH type="full" alt="Screenshot (14625).png"]22967[/ATTACH] [ATTACH type="full" alt="Screenshot (14626).png"]22968[/ATTACH] [ATTACH type="full" alt="Screenshot (14629).png"]22969[/ATTACH][ATTACH type="full" alt="Screenshot (14630).png"]22970[/ATTACH] [ATTACH type="full" alt="Screenshot (14632).png"]22971[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
MRI-guided Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top